Company Profile
Sangamo Therapeutics, Inc. Stock Price, News & Analysis
- Ticker:
- SGMO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.07 USD (-57.54%)
Close
Last updated: June 23, 2026
—
Market cap
Why the stock is moving
Current closing-price context is not available for SGMO.
Company overview
Genomic Medicine Company
Sangamo Therapeutics translates zinc finger epigenetic regulators, gene therapy, and delivery technologies into potential medicines for severe neurological and other serious diseases.
Zinc Finger Technology Platform
Sangamo’s engineered zinc finger proteins can be configured for gene regulation, editing, and epigenetic control. The platform supports both internally developed medicines and partnered programs across neurological and systemic diseases.
ST-920 in Fabry Disease
Isaralgagene civaparvovec, formerly ST-920, is Sangamo’s wholly owned gene therapy candidate for Fabry disease. The company is pursuing the FDA Accelerated Approval pathway through a rolling BLA submission and has submitted the preclinical and clinical modules while advancing the chemistry, manufacturing, and controls module.
Neurology Pipeline
Sangamo’s neurology pipeline includes ST-503 for intractable chronic neuropathic pain caused by small fiber neuropathy. The company has also held constructive discussions with the U.K. MHRA regarding a potential study in prion disease.
Internal and Partnered Development
Sangamo combines wholly owned programs such as its Fabry gene therapy with collaborations that apply zinc finger technology to partner-selected targets. This model provides external validation and funding while preserving direct ownership of selected high-value assets.
Future catalysts
Completion of the CMC module for the rolling BLA submission of isaralgagene civaparvovec could occur as early as summer 2026, subject to Sangamo obtaining sufficient additional funding.
The companion diagnostic antibody assay has been accepted by the FDA’s CDRH for PMA review, making future PMA and BLA interactions important regulatory milestones for the Fabry program.
Six sites have been activated for the Phase 1/2 STAND study of ST-503, with enrollment and initial data expected to test the chronic neuropathic pain program.
Recent news
- 01
Sangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and Astellas
Source: Sangamo Therapeutics, Inc.
- 02
Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders
Source: Sangamo Therapeutics, Inc.
- 03
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results
Source: Sangamo Therapeutics, Inc.
- 04
Sangamo Therapeutics Announces First Quarter 2026 Earnings Call
Source: Sangamo Therapeutics, Inc.
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Sangamo Therapeutics, Inc. (SGMO)?
Sangamo Therapeutics, Inc. (SGMO) most recently closed at 0.07 USD, a -57.54% move versus the previous session.
What does Sangamo Therapeutics, Inc. do?
Genomic Medicine Company Sangamo Therapeutics translates zinc finger epigenetic regulators, gene therapy, and delivery technologies into potential medicines for severe neurological and other serious diseases. Zinc Finger Technology Platform Sangamo’s engineered zinc finger proteins can be configured for gene regulation, editing, and epigenetic control. The...
On which exchange is SGMO stock listed?
Sangamo Therapeutics, Inc. (SGMO) is associated with NASDAQ, United States, Biopharma.
What is ST-920?
ST-920 in Fabry Disease Isaralgagene civaparvovec, formerly ST-920, is Sangamo’s wholly owned gene therapy candidate for Fabry disease.
Which conditions is Sangamo Therapeutics, Inc. targeting with ST-920?
Sangamo Therapeutics, Inc. is associated with neurology, genetic disease based on its company overview and current catalyst commentary.
How does Sangamo Therapeutics, Inc. describe recent progress with ST-920?
Completion of the CMC module for the rolling BLA submission of isaralgagene civaparvovec could occur as early as summer 2026, subject to Sangamo obtaining sufficient additional funding. The companion diagnostic antibody assay has been accepted by the FDA’s CDRH for PMA review, making future PMA and BLA interactions important regulatory milestones for the...
What is ST-503?
Neurology Pipeline Sangamo’s neurology pipeline includes ST-503 for intractable chronic neuropathic pain caused by small fiber neuropathy.
What should investors watch for with ST-503?
Six sites have been activated for the Phase 1/2 STAND study of ST-503, with enrollment and initial data expected to test the chronic neuropathic pain program.